Innovation vs. invention

IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.

By Taren Grom • Feb. 9, 2022

Saniona's CEO on why it takes a village to develop treatments for a rare disease

Saniona built its village by first hiring a head of patient advocacy.

By Kim Ribbink • Feb. 8, 2022

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Gaining real-world results from a decentralized trial

Lark’s principal Investigator OraLee Branch hopes a DCT will lead the company to their true audience.

By Kelly Bilodeau • Feb. 8, 2022

Why 23andMe's first solo clinical trial is a big deal

It's the first test for a compound developed with the help of the company's genetic data — and there could be plenty more to come. 

By Taren Grom • Feb. 7, 2022

Pharma's pain points with AI

Looking beyond the buzz and at the challenges associated with AI.

By Meagan Parrish • Feb. 7, 2022

Safety Monitoring: What does ePRO have to do with it?

Safety monitoring is critical to clinical trials. Learn how ePRO can play a role. Read the article.

Feb. 7, 2022

Komodo Health's partnership with Chan Zuckerberg Initiative gives 50 rare disease patient organizations access to next-generation analytics

With 330 million patient healthcare encounters in its database, Komodo assists advocacy organizations in gaining insights on specific patient populations.

By Robin Robinson • Feb. 3, 2022

PTC's vice president of patient relations outlines the importance of patient input in rare disease R&D

You can't know what matters to rare disease patients unless you ask them.

By Kim Ribbink • Feb. 3, 2022

New Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality

Read what Capsida CEO Peter Anastasiou has planned for his new role. 

By Taren Grom • Feb. 3, 2022

Biopharma's R&D leaders on how technology can accelerate drug development

How emerging digital tools are providing enhanced clinical insights and improved trial results.

By Taren Grom • Jan. 27, 2022

Sanofi's chief scientist on why 'this is the moment' for AI in Big Pharma

How a $5.2 billion AI investment is enabling the French pharma to accelerate drug development. 

By Meagan Parrish • Jan. 27, 2022

With its wealth of patient data, Walgreens is looking to disrupt the clinical trial space

How the mega-pharmacy’s clinical trials officer is looking to capitalize on its deep well of patient data to create an interconnected healthcare system of the future.

By Taren Grom • Jan. 26, 2022

Woman of the Week: Janssen's Dr. Sylvie Laquerre

Why following the science is crucial when bringing new compounds to market.  

By Taren Grom • Jan. 26, 2022

How AI is helping pharma solve some of its COVID problems

With the pressure still on pharma to innovate quickly and go digital, the use-cases for AI are increasing in stride.

By Meagan Parrish • Jan. 25, 2022

One man's quest to boost the patient's role in clinical trials

How a personal diagnosis inspired Craig Lipset to transform patient involvement in medical research.

By Robin Robinson • Jan. 24, 2022

Leaders predict improving patient engagement will lead to growth opportunities

Why patient engagement is key to successful business growth.

By Taren Grom • Jan. 24, 2022

Evofem CEO Saundra Pelletier aims to level the playing field between men's and women's health

Evofem CEO and PharmaVoice100, Saundra Pelletier, discusses funding challenges for women's health.

By Alexandra Pecci • Jan. 23, 2022

Vaxxinity looks to pioneer the next revolution in pharma

With a one-of-a-kind platform and novel candidates for major indications, Vaxxinity wants to disrupt the industry’s paradigm of success. 

By Meagan Parrish • Jan. 14, 2022

Pharma execs reveal the industry's most pressing issues

Several market factors — including COVID — are driving changes and trends in the industry.

By Taren Grom • Jan. 14, 2022

Welcome to the new PharmaVoice

A similar mission, a new format, and our plans for PharmaVoice's next chapter.

By Davide Savenije • Jan. 13, 2022

5 trends shaping clinical trial regulations in 2022

As agencies respond to innovations in pharma, notable shifts in 2022 are on the way.

By Meagan Parrish • Jan. 11, 2022

Ovid's CEO shares his vision for rare disease developments

Jeremy Levin, chairman and CEO of Ovid Therapeutics discusses the keys to success in rare disease innovation.

By Kim Ribbink • Jan. 10, 2022

Australian firefighters raise funds for ALS research

Funding for rare disease clinical trials can be a challenge, but in Australia, firefighters gear up to raise money for ALS. 

By Kim Ribbink • Jan. 5, 2022

Rare disease innovation in 2022

More companies are targeting gene therapies for rare disease treatments.

By Kim Ribbink • Jan. 5, 2022

Speak Out: The Value of Using Neutral Analysis in Life Sciences Disputes

Imagine that you have multiple published and peer-reviewed clinical trials and time is of the essence to get your vaccine to market. Unfortunately, you are involved in a lawsuit for patent infringement with a competitor. Will you go to trial? What are your odds of prevailing? HAVE THE RIGHT ST...

By Hon. Gregory M. Sleet (Ret.) • Nov. 15, 2021